KYMR
Kymera Therapeutics·NASDAQ
--
--(--)
--
--(--)
6.31 / 10
Outperform
Analyst sentiment is overwhelmingly bullish with two active analysts issuing Buy/Strong Buy ratings. Fund-flow data show strong overall and block inflows, but medium and large orders lean negative, hinting at distribution pressure. Together, the analyst and liquidity picture supports the positive ratings yet warns of potential short-term pullbacks.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
50%
Buy
50%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-01-28
InstitutionBarclays
Times predicted4
Historical Win Rate75.0%
What is the market sentiment for KYMR?
- KYMR holds a Bearish analyst rating, with 50% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 6.31/10 (Outperform).
